Cellectar Biosciences Statistics
Total Valuation
CLRB has a market cap or net worth of $20.14 million. The enterprise value is $13.32 million.
| Market Cap | 20.14M |
| Enterprise Value | 13.32M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 7.99 million shares outstanding. The number of shares has increased by 141.46% in one year.
| Current Share Class | 7.99M |
| Shares Outstanding | 7.99M |
| Shares Change (YoY) | +141.46% |
| Shares Change (QoQ) | +3.20% |
| Owned by Insiders (%) | 2.16% |
| Owned by Institutions (%) | 17.35% |
| Float | 7.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.80 |
| P/TBV Ratio | 7.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.90 |
| Quick Ratio | 1.71 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -290.42% and return on invested capital (ROIC) is -170.99%.
| Return on Equity (ROE) | -290.42% |
| Return on Assets (ROA) | -102.96% |
| Return on Invested Capital (ROIC) | -170.99% |
| Return on Capital Employed (ROCE) | -358.20% |
| Weighted Average Cost of Capital (WACC) | 6.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.89M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.26% in the last 52 weeks. The beta is 0.54, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -68.26% |
| 50-Day Moving Average | 2.81 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 45.41 |
| Average Volume (20 Days) | 148,335 |
Short Selling Information
The latest short interest is 258,202, so 3.23% of the outstanding shares have been sold short.
| Short Interest | 258,202 |
| Short Previous Month | 777,622 |
| Short % of Shares Out | 3.23% |
| Short % of Float | 3.30% |
| Short Ratio (days to cover) | 0.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.37M |
| Pretax Income | -20.84M |
| Net Income | -20.84M |
| EBITDA | -22.16M |
| EBIT | -22.37M |
| Earnings Per Share (EPS) | -$6.35 |
Balance Sheet
The company has $8.35 million in cash and $1.53 million in debt, with a net cash position of $6.82 million or $0.85 per share.
| Cash & Cash Equivalents | 8.35M |
| Total Debt | 1.53M |
| Net Cash | 6.82M |
| Net Cash Per Share | $0.85 |
| Equity (Book Value) | 4.72M |
| Book Value Per Share | 0.66 |
| Working Capital | 4.39M |
Cash Flow
In the last 12 months, operating cash flow was -$18.58 million and capital expenditures -$9,258, giving a free cash flow of -$18.59 million.
| Operating Cash Flow | -18.58M |
| Capital Expenditures | -9,258 |
| Depreciation & Amortization | 210,701 |
| Net Borrowing | n/a |
| Free Cash Flow | -18.59M |
| FCF Per Share | -$2.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -141.46% |
| Shareholder Yield | -141.46% |
| Earnings Yield | -103.48% |
| FCF Yield | -92.30% |
Analyst Forecast
The average price target for CLRB is $10.33, which is 309.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.33 |
| Price Target Difference | 309.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 24, 2025. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jun 24, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |